Literature DB >> 24888751

Trends in psychopharmacologic treatment of tic disorders in children and adolescents in Germany.

Christian J Bachmann1, Veit Roessner, Gerd Glaeske, Falk Hoffmann.   

Abstract

Data on medical treatment of children and adolescents with tic disorders are scarce. This study examined the administrative prevalence of psychopharmacological prescriptions in this patient group in Germany. Data of the largest German health insurance fund were analysed. In outpatients aged 0-19 years with diagnosed tic disorder, psychotropic prescriptions were evaluated for the years 2006 and 2011. In 2011, the percentage of psychotropic prescriptions was slightly higher than in 2006 (21.2 vs. 18.6%). The highest prescription prevalence was found in Tourette syndrome (51.5 and 53.0%, respectively). ADHD drugs were most frequently prescribed, followed by antipsychotics. In 2011, prescriptions of second generation antipsychotics (SGA) were higher and prescriptions of first generation antipsychotics (FGA) lower than in 2006. Concerning prescribed antipsychotic substances, in 2011 risperidone prescriptions were higher and tiapride prescriptions lower. Paediatricians issued 37.4%, and child and adolescent psychiatrists issued 37.1% of psychotropic prescriptions. The FGA/SGA ratio was highest in GPs (1.25) and lowest in child and adolescent psychiatrists (0.96). From 2006 to 2011, there was only a slight increase in psychotropic prescriptions for children and adolescents with a diagnosis of tic disorder in Germany, which stands in contrast towards the significant increase in psychotropic prescriptions in other child and adolescent psychiatric disorders (e.g. ADHD). There were marked differences in treatment patterns by tic disorder subgroups, with Tourette syndrome patients receiving most frequently psychopharmacotherapy. Risperidone prescriptions increased, probably reflecting a switch in prescribing practice towards up-to-date treatment guidelines. In primary care physicians, dissemination of current tic disorder treatment guidelines might constitute an important educational goal.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24888751     DOI: 10.1007/s00787-014-0563-6

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  37 in total

1.  Is it a tic?--Twenty seconds to make a diagnosis.

Authors:  Jennifer Paszek; Bettina Pollok; Katja Biermann-Ruben; Kirsten Müller-Vahl; Veit Roessner; Götz Thomalla; Mary M Robertson; Michael Orth; Alfons Schnitzler; Alexander Münchau
Journal:  Mov Disord       Date:  2010-06-15       Impact factor: 10.338

2.  A placebo-controlled trial of risperidone in Tourette syndrome.

Authors:  L Scahill; J F Leckman; R T Schultz; L Katsovich; B S Peterson
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

3.  A phenomenological investigation of women with Tourette or other chronic tic disorders.

Authors:  Adam B Lewin; Tanya K Murphy; Eric A Storch; Christine A Conelea; Douglas W Woods; Lawrence D Scahill; Scott N Compton; Samuel H Zinner; Cathy L Budman; John T Walkup
Journal:  Compr Psychiatry       Date:  2011-08-24       Impact factor: 3.735

Review 4.  First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants.

Authors:  Veit Roessner; Monika Robatzek; Guido Knapp; Tobias Banaschewski; Aribert Rothenberger
Journal:  Dev Med Child Neurol       Date:  2006-07       Impact factor: 5.449

5.  Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder.

Authors:  K D Gadow; J Sverd; J Sprafkin; E E Nolan; S Grossman
Journal:  Arch Gen Psychiatry       Date:  1999-04

6.  Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany.

Authors:  Christian J Bachmann; Thomas Manthey; Inge Kamp-Becker; Gerd Glaeske; Falk Hoffmann
Journal:  Res Dev Disabil       Date:  2013-06-07

7.  Use of antipsychotic drugs among Dutch youths between 1997 and 2005.

Authors:  Luuk J Kalverdijk; Hilde Tobi; Paul B van den Berg; Janelle Buiskool; Leonie Wagenaar; Ruud B Minderaa; Lolkje T W de Jong-van den Berg
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

8.  The presence of comorbidity in Tourette syndrome increases the need for pharmacological treatment.

Authors:  Nanette M M M Debes; Helle Hjalgrim; Liselotte Skov
Journal:  J Child Neurol       Date:  2009-06-03       Impact factor: 1.987

Review 9.  Current controversies on the role of behavior therapy in Tourette syndrome.

Authors:  Lawrence Scahill; Douglas W Woods; Michael B Himle; Alan L Peterson; Sabine Wilhelm; John C Piacentini; Kevin McNaught; John T Walkup; Jonathan W Mink
Journal:  Mov Disord       Date:  2013-05-16       Impact factor: 10.338

10.  The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 2: tentative explanations for differing prevalence figures in GTS, including the possible effects of psychopathology, aetiology, cultural differences, and differing phenotypes.

Authors:  Mary M Robertson
Journal:  J Psychosom Res       Date:  2008-10-02       Impact factor: 3.006

View more
  8 in total

1.  The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.

Authors:  C Rafaniello; M Sessa; F F Bernardi; M Pozzi; S Cheli; D Cattaneo; S Baldelli; M Molteni; R Bernardini; F Rossi; E Clementi; C Bravaccio; S Radice; A Capuano
Journal:  Pharmacogenomics J       Date:  2017-07-18       Impact factor: 3.550

2.  Tourette Syndrome research highlights 2014.

Authors:  Cheryl A Richards; Kevin J Black
Journal:  F1000Res       Date:  2015-03-16

3.  Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study.

Authors:  Nicholas Cothros; Davide Martino; Carly McMorris; David Stewart; Ali Tehrani; Tamara Pringsheim
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-07-15

4.  An International Survey of Health Care Services Available to Patients With Tourette Syndrome.

Authors:  Tracy Bhikram; Rana Elmaghraby; Elia Abi-Jaoude; Paul Sandor
Journal:  Front Psychiatry       Date:  2021-02-26       Impact factor: 4.157

Review 5.  European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.

Authors:  Veit Roessner; Heike Eichele; Jeremy S Stern; Liselotte Skov; Renata Rizzo; Nanette Mol Debes; Péter Nagy; Andrea E Cavanna; Cristiano Termine; Christos Ganos; Alexander Münchau; Natalia Szejko; Danielle Cath; Kirsten R Müller-Vahl; Cara Verdellen; Andreas Hartmann; Aribert Rothenberger; Pieter J Hoekstra; Kerstin J Plessen
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-11-10       Impact factor: 4.785

6.  Psychotherapy Combined with Western Medicine in the Treatment of Children with Tic Disorder: Systematic Review and Meta-Analysis.

Authors:  Yamin Kong; Xueyuan Zhang; Bingxiang Ma
Journal:  Comput Math Methods Med       Date:  2022-04-04       Impact factor: 2.238

7.  Outpatient Treatment of Tic Disorders Among Children and Adults.

Authors:  Joseph L Smith; Sean Gregory; Nicole McBride; Tanya K Murphy; Eric A Storch
Journal:  Mov Disord Clin Pract       Date:  2017-03-11

Review 8.  Tourette syndrome research highlights 2015.

Authors:  Cheryl A Richards; Kevin J Black
Journal:  F1000Res       Date:  2016-06-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.